普乐安片联合萘哌地尔治疗前列腺增生的疗效观察

目的分析普乐安片联合萘哌地尔治疗前列腺增生的临床效果。方法选择2014年3月-2017年3月在焦作市妇幼保健院治疗的前列腺增生患者88例,随机分为对照组(44例)和治疗组(44例)。对照组患者口服萘哌地尔片,25mg/次,1次/d。治疗组在对照组的基础上口服普乐安片,4片/次,3次/d。两组患者均治疗30d。观察两组患者临床疗效,同时比较治疗前后两组患者残余尿量、尿流速、国际前列腺症状评分(IPSS)和QOL评分。结果治疗后,对照组和治疗组临床有效率分别为75.00%和93.18%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组残余尿量明显减少(P<0.05),而平均尿流速(Qave)和最大尿流速(Qmax)均明显增加(P<0.05),且治疗组残余尿量和尿流速明显优于对照组(P<0.05)。治疗后,两组IPSS和QOL评分均显著降低(P<0.05),且治疗组明显低于对照组(P<0.05)。结论普乐安片联合萘哌地尔治疗前列腺增生患者临床效果较好,可明显改善患者排尿情况,优化前列腺功能,提高患者生活质量。

Clinical observation of Pulean Tablets combined with napidil in treatment of prostatic hyperplasia

Objective To systematically evaluate the efficacy and safety of extract of Ginkgo biloba preparations (EGb) for Alzheimer''s disease. Methods A randomized controlled trial (RCT) of EGb for Alzheimer''s disease was conducted on PubMed, Web of Science, Embase, CBM, CNKI, VIP and Wanfang databases from inception to October 29, 2019. Two evaluators independently screened the literature for quality evaluation, and RevMan 5.3.5 software was used for statistical analysis. Results A total of 21 RCTs were included, including 1 643 patients. Meta-analysis results showed:(1) Compared with citicoline, EGb can improve MMSE[MD=3.80, 95%CI(2.05, 5.55), P<0.000 1], ADL scores[MD=-3.30, 95%CI(-4.75, -1.85), P<0.000 01] and total effective rate[OR=3.69, 95%CI(1.87, 7.27), P=0.000 2] more effectively; (2) Compared with the use of only basic treatment or other drugs alone, the combination of EGb can improve MMSE[MD=2.68, 95%CI(2.35, 3.02), P<0.000 01], ADL score[MD=-3.48, 95%CI(-4.36, -2.60), P<0.000 01] and total effective rate[OR=3.50, 95%CI(1.09, 11.22), P=0.03] more effectively; (3) Compared with placebo or no intervention, EGb can effectively improve MMSE[MD=1.82, 95%CI(0.33, 3.32), P=0.02] and ADL scores[MD=-7.00, 95%CI(-10.93, -3.07), P=0.0005]; (4) Compared with donepezil monotherapy, the combination of donepezil and EGb can improve MMSE[MD=1.82, 95%CI(0.33, 3.32), P=0.02], ADL scores[MD=-4.29, 95%CI(-5.58, -2.99), P<0.000 01] and total effective rate[OR=2.95, 95%CI(1.42, 6.13), P=0.004] more effectively; (5) EGb has a significantly lower effect on the MMSE score[MD=-1.79, 95%CI(-2.39, -1.20), P<0.000 01] and total effective rate[OR=0.15, 95%CI(0.08, 0.30), P<0.000 01] than donepezil. Conclusions EGb are effective in the treatment of Alzheimer''s disease, and there is no significant difference in adverse reactions.